Fabrication and Optimization of a Silodosin In Situ-Forming PLGA Implants for the Treatment of Benign Prostatic Hyperplasia: In Vitro and In Vivo Study
Pharmaceutics · 25.10.2024 · 16 (11) · 1364
DOI: 10.3390/pharmaceutics16111364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 25.10.2024. Verfasst von Rabab A Husseini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Lower urinary tract symptoms (LUTSs) related to benign prostatic hyperplasia (BPH) are common in older men, and alpha-adrenoceptor blockers continue to be a key part of managing these symptoms. This study aimed to formulate injectable poly (lactic-co-glycolic acid) (PLGA) in situ-forming implants (ISFIs) loaded with silodosin (SLD) to address symptoms associated with BPH. This method, which ensures prolonged therapeutic effects of SLD, is intended to decrease dosing frequency and improve treatment outcomes, leading to better patient adherence.
Methods
An appropriate solvent with favorable PLGA solubility, viscosity, and in vitro release profile was selected. Additionally, an I-optimal design was employed as an optimization technique. An in vivo study in albino male rats was conducted to investigate prostate-specific antigens (PSAs), prostate weight and prostatic index, histopathology, and SLD pharmacokinetics.
Results
The optimized formulation showed experimental values of 29.25% for the initial burst after 2 h and 58.23% for the cumulative release of SLD after 10 days. Pharmacokinetic data revealed that the SLD–ISFI formulation had lower Cmax and higher AUC values than subcutaneous (SC) pure SLD and oral commercial SLD capsule, indicating the controlled-release impact and improved bioavailability of the ISFI systems. SLD–ISFI produced a marked drop in the prostatic index by 2.09-fold compared to the positive control. Serum PSA level decreased significantly from 0.345 ± 0.007 to 0.145 ± 0.015 ng/mL after SLD–ISFI injection compared to the positive control.
Conclusions
This study indicated that the optimized SLD–ISFI formulation proved its efficacy in managing BPH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
- Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44519, Egypt.
- Nanotechnology Research Center (NTRC), The British University in Egypt (BUE), Cairo 11837, Egypt.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
- Department of Pharmaceutics, Faculty of Pharmacy, Najran University, Najran 11001, Saudi Arabia.
ORCID-Profile: Dina M Abdelnabi
Zitieren
APA
Husseini, R. A., Ibrahim, T. M., Hamed, E., Gomaa, E., Faisal, M. M., Wan, G., Amin, M., Alkolaib, A. M., & Abdelnabi, D. M. (2024). Fabrication and Optimization of a Silodosin In Situ-Forming PLGA Implants for the Treatment of Benign Prostatic Hyperplasia: In Vitro and In Vivo Study. Pharmaceutics, 16(11), 1364. https://doi.org/10.3390/pharmaceutics16111364
Vancouver
Husseini RA, Ibrahim TM, Hamed E, Gomaa E, Faisal MM, Wan G, et al. Fabrication and Optimization of a Silodosin In Situ-Forming PLGA Implants for the Treatment of Benign Prostatic Hyperplasia: In Vitro and In Vivo Study. Pharmaceutics. 2024;16(11):1364. doi:10.3390/pharmaceutics16111364
BibTeX
@article{Husseini2024,
author = {Husseini, Rabab A and Ibrahim, Tarek M and Hamed, Eslam and Gomaa, Eman and Faisal, Mennatullah M and Wan, Ghadeer and Amin, Manna and Alkolaib, Ali M and Abdelnabi, Dina M},
title = {Fabrication and Optimization of a Silodosin In Situ-Forming PLGA Implants for the Treatment of Benign Prostatic Hyperplasia: In Vitro and In Vivo Study},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {11},
pages = {1364},
doi = {10.3390/pharmaceutics16111364}
}
EUVIMED